COMPASS Pathways (CMPS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
The 2026 Annual General Meeting (AGM) will be held on May 27, 2026, in London, with proxy materials distributed to shareholders and ADS holders as of April 6, 2026.
Shareholders are encouraged to vote on ten ordinary resolutions, including director elections, auditor appointments, remuneration reports, and executive compensation.
The Board unanimously recommends voting in favor of all resolutions, viewing them as aligned with the company's best interests.
Voting matters and shareholder proposals
Resolutions include re-election/election of four directors, re-appointment and ratification of PricewaterhouseCoopers LLP as auditors, authorization of auditor remuneration, receipt of annual accounts, and advisory votes on remuneration and executive compensation.
All resolutions require a simple majority; advisory votes on remuneration and compensation are non-binding but will be considered by the Board.
Shareholders may submit proposals for future meetings and have rights to call general meetings under UK law.
Board of directors and corporate governance
The Board is divided into three classes with staggered terms; current nominees include Justin Gover, Daphne Karydas, Kathleen Tregoning, and Jeffrey Jonas.
Board committees include Audit and Risk, Compensation and Leadership Development, Nominating and Corporate Governance, and Scientific Committees, all composed of independent directors.
The Board separates the roles of Chair and CEO and conducts annual self-evaluations.
Shareholder communications and director nomination processes are formalized.
Latest events from COMPASS Pathways
- Regulatory momentum and clinical advances are driving rapid commercialization of psychedelic therapies.CMPS
Needham Virtual Psychedelics Forum28 Apr 2026 - COMP360 nears approval with strong phase III results, leveraging SPRAVATO infrastructure for launch.CMPS
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - COMP360 is set to transform TRD and PTSD care with rapid efficacy and commercial launch readiness.CMPS
KOL Event13 Apr 2026 - COMP360 achieved rapid, durable, and significant efficacy in TRD with strong safety in Phase 3 trials.CMPS
Study update11 Apr 2026 - COMP360 advances toward NDA submission and commercial launch, with strong clinical and financial positioning.CMPS
Q4 202524 Mar 2026 - COMP360 targets year-end launch for TRD, with strong data, access focus, and solid financial runway.CMPS
Stifel 2026 Virtual CNS Forum18 Mar 2026 - Phase III data show rapid, sustained TRD improvement and strong safety, supporting regulatory progress.CMPS
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Phase III COMP360 trials advance with key data soon; commercial and PTSD plans progress.CMPS
TD Cowen 45th Annual Healthcare Conference3 Feb 2026 - New CPT codes, research collaborations, and REMS support safe, scalable psychiatric treatment access.CMPS
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference3 Feb 2026